BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol 2020;95:672-90. [PMID: 32086970 DOI: 10.1002/ajh.25764] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Sim B, Ng JY, Teh BW, Talaulikar D. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule. Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2131424] [Reference Citation Analysis]
2 Yang P, Qu Y, Wang M, Chu B, Chen W, Zheng Y, Niu T, Qian Z. Pathogenesis and treatment of multiple myeloma. MedComm (2020) 2022;3:e146. [PMID: 35665368 DOI: 10.1002/mco2.146] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Vekemans MC, Doyen C, Caers J, Wu K, Kentos A, Mineur P, Michaux L, Delforge M, Meuleman N. Recommendations on the management of multiple myeloma in 2020. Acta Clin Belg 2022;77:445-61. [PMID: 33355041 DOI: 10.1080/17843286.2020.1860411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Geraldes C, Neves M, Chacim S, da Costa FL. Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists. Front Oncol 2022;11:817762. [DOI: 10.3389/fonc.2021.817762] [Reference Citation Analysis]
5 Zhai Y, Ye X, Hu F, Xu J, Guo X, Cao Y, Lin Z, Zhou X, Guo Z, He J. Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States. Front Cardiovasc Med 2021;8:735466. [PMID: 34646873 DOI: 10.3389/fcvm.2021.735466] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
6 Gertz MA, Vaxman I. Should high risk smoldering myeloma be treated outside a clinical trial: NO. Leuk Lymphoma 2021;:1-3. [PMID: 34261405 DOI: 10.1080/10428194.2021.1951723] [Reference Citation Analysis]
7 Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel) 2021;9:3. [PMID: 33498356 DOI: 10.3390/medsci9010003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
8 Manni S, Fregnani A, Barilà G, Zambello R, Semenzato G, Piazza F. Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research. Front Oncol 2020;10:802. [PMID: 32500036 DOI: 10.3389/fonc.2020.00802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Wongsaengsak S, Kopel J, Behera TR, Chakraborty R, Ball S. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials. Br J Haematol 2020;190:e95-7. [PMID: 32400886 DOI: 10.1111/bjh.16735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]